Natera
NTRA
$395.56
-1.27%
Natera, Inc. is a molecular diagnostics and bioinformatics company that develops cell-free DNA (cfDNA) testing platforms, with flagship products including the Panorama non-invasive prenatal test (NIPT), Horizon carrier screening, Signatera molecular residual disease (MRD) testing for oncology, and Prospera for organ transplant rejection monitoring. The company has established itself as a category leader in the rapidly growing MRD testing market, where Signatera competes with offerings from Guardant Health and other diagnostics players, while its women's health franchise provides a durable recurring revenue base. The current investor narrative is dominated by Signatera's accelerating oncology revenue ramp, recent international regulatory wins including a second Japan PMDA approval for bladder cancer companion diagnostics, and the company's transition toward profitability, with Q2 2026 revenue growing 37.7% year-over-year to $752.75 million. The stock has attracted high-profile institutional interest, including a disclosed position by billionaire investor Stanley Druckenmiller, reflecting growing conviction that Natera's MRD platform represents a multi-billion-dollar opportunity as reimbursement expands and clinical evidence accumulates.…
NTRA
Natera
$395.56
Related headlines
Investment Opinion: Should I buy NTRA Today?
Based on the synthesis of fundamentals, valuation, and analyst sentiment, the objective rating for Natera is a Hold. The core thesis is that Natera is a high-quality growth company with a dominant position in the MRD market, but the stock's current price of $410.35 exceeds the average analyst target of $361.16 and trades at a premium valuation (13.58x PS), leaving limited near-term upside. The strong_buy consensus (recommendation mean 1.39) and high target of $475.00 reflect optimism, but the risk/reward is balanced at current levels.
Supporting evidence for the Hold includes: 1) Revenue growth of 37.7% YoY in Q2 2026, significantly above the industry average of 5-10%; 2) Gross margin of 64.46%, stable and above the industry average of 50-55%; 3) Positive trailing twelve-month free cash flow of $71.70 million and a fortress balance sheet with $1.09 billion in cash; 4) The stock has surged 156.13% over the past year, far outpacing the S&P 500's 15.01% gain, and now trades at 96% of its 52-week range. The implied downside to the average analyst target is -11.99%, while the high target offers +15.75% upside, indicating a skewed risk/reward.
The biggest risks that could invalidate the thesis include: 1) A slowdown in revenue growth below 30% could trigger multiple compression; 2) Continued net losses and negative operating cash flow could delay the path to profitability; 3) Competitive pressures from Guardant Health and reimbursement challenges. The rating would upgrade to Buy if the stock pulls back to the $350-$370 range (near the average target) or if revenue growth accelerates above 40% with improving margins. It would downgrade to Sell if revenue growth decelerates below 20% or if gross margins fall below 60%. Relative to its history, the PS ratio of 13.58x is near the low end of its 5-year range (average ~30x), but relative to peers, it is overvalued. Thus, the stock is fairly valued to slightly overvalued at current levels.
Sign up to view all
NTRA 12-Month Price Forecast
Natera is a high-growth diagnostics leader with a strong competitive position in MRD testing, but the stock's valuation and recent price surge have created a balanced risk/reward. The company's revenue growth is impressive, but it remains unprofitable, and the stock trades at a premium to peers and above the average analyst target. The recent Japan PMDA approval and institutional interest are positive, but the high beta and potential for multiple compression warrant caution. I would upgrade to bullish if the stock pulls back to the $350-$370 range or if revenue growth accelerates above 40% with clear profitability. I would downgrade to bearish if revenue growth falls below 25% or if reimbursement challenges emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $377.43 and implied upside of -4.6% versus the current price.
Average Target
$377.43
0 analysts
Implied Upside
-4.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $480
Analyst target range
Natera is covered by 22 analysts, with a consensus recommendation of "strong_buy" (recommendation mean of 1.39 on a scale where 1 is Strong Buy and 5 is Strong Sell), reflecting overwhelmingly bullish sentiment. The average price target is $361.16, which implies a downside of -11.99% from the current price of $410.35, a rare situation where the stock has run ahead of consensus targets. This disconnect suggests that analysts have been playing catch-up with the stock's rapid ascent, and the recent institutional ratings from firms like RBC Capital (Outperform), UBS (Buy), Citigroup (Buy), and JP Morgan (Overweight) indicate that the bullish thesis remains intact, but target prices may need to be revised upward to reflect the new price reality. The consensus leans strongly bullish on fundamentals, but the current price exceeding the average target signals that near-term upside may be limited unless analysts raise their estimates.
The target price range spans from a low of $280.00 to a high of $475.00, a spread of $195.00 (or 69.6% of the low target), indicating significant dispersion in analyst views and high uncertainty about the company's future trajectory. The high target of $475.00 implies a +15.75% upside from current levels and likely assumes continued Signatera adoption, successful international expansion (including the recent Japan PMDA approvals), and a faster-than-expected path to profitability. The low target of $280.00 implies a -31.76% downside and likely prices in risks such as reimbursement headwinds, competitive pressure in the MRD space, or slower-than-expected margin expansion. The wide spread, combined with the fact that the stock is trading above the average target, suggests that the market is pricing in a best-case scenario, and any negative news could lead to a sharp correction as analysts reassess their models. The estimated EPS average of $4.23 for the forward year, if achieved, would represent a dramatic swing to profitability and could justify higher targets, but execution risk remains high.
Bulls vs Bears: NTRA Investment Factors
The bull case for Natera rests on its exceptional revenue growth (37.7% YoY), fortress balance sheet, and leadership in the high-growth MRD market, supported by a strong analyst consensus and recent international regulatory wins. However, the bear case highlights that the stock trades at a significant premium to peers (13.58x PS vs. 3x-8x sector) and above the average analyst target, with persistent net losses and high volatility. Currently, the bull evidence is stronger on fundamentals, but the bear evidence is stronger on valuation and near-term risk/reward. The single most important tension is whether Signatera's adoption and reimbursement can sustain 30%+ growth long enough to justify the premium multiple; if growth decelerates, the stock could face a severe multiple compression.
Bullish
- Explosive revenue growth: Q2 2026 revenue grew 37.7% YoY to $752.75 million, accelerating from 8.05% QoQ growth and a multi-quarter trend that saw revenue rise from $501.83 million in Q1 2025 to $752.75 million in Q2 2026. This sustained acceleration is driven by Signatera's oncology ramp and expanding reimbursement, with analyst estimates projecting $5.99 billion for the current year.
- Fortress balance sheet: Natera holds $1.09 billion in cash with a debt-to-equity ratio of just 0.125 and a current ratio of 3.39, providing ample liquidity to fund R&D and commercialization without dilutive financing. The company also generated positive trailing twelve-month free cash flow of $71.70 million, demonstrating improving cash generation.
- Strong analyst consensus: 22 analysts rate the stock a 'strong_buy' with a recommendation mean of 1.39, and the average price target of $361.16 implies a -11.99% downside only because the stock has surged past targets. The high target of $475.00 suggests 15.75% upside, and recent institutional ratings from RBC, UBS, Citigroup, and JP Morgan remain bullish.
- Signatera international expansion: The September 23, 2026 Japan PMDA approval for Signatera as a bladder cancer companion diagnostic marks the second approval in three months, opening Japan's bladder cancer market and reinforcing Natera's MRD leadership. This regulatory momentum supports long-term growth and diversifies revenue beyond the U.S.
Bearish
- Price exceeds analyst targets: The current price of $410.35 is 13.6% above the average analyst target of $361.16, a rare disconnect that suggests the stock has run ahead of fundamental consensus. Unless analysts aggressively raise targets, near-term upside may be limited, and any negative news could trigger a sharp correction as targets are reassessed.
- Extreme valuation multiples: The trailing PS ratio of 13.58x and EV/Sales of 21.44x represent a 70-100% premium to the diagnostics sector median of 3x-8x. The forward PS of ~10x still embeds optimistic 30%+ growth assumptions, and any deceleration could cause significant multiple compression even if revenue continues to grow.
- Persistent net losses: Despite revenue growth, Natera reported a net loss of $66.97 million in Q2 2026, with a net margin of -8.90% and negative ROE of -12.16%. The company has only one recent profitable quarter (Q4 2025), and sustained profitability remains unproven, with forward EPS estimates of $4.23 requiring a dramatic swing.
- High volatility and drawdown risk: With a beta of 1.534, the stock is 53% more volatile than the market, and it experienced a maximum drawdown of -28.2% over the past year. The current price is near the 52-week high of $427.47, leaving little margin for error and increasing the risk of a sharp mean-reversion pullback.
NTRA Technical Analysis
Natera is in a powerful, sustained uptrend, with the stock up 156.13% over the past year and 79.32% year-to-date, dramatically outperforming the S&P 500's 15.01% and 12.86% respective gains. At a current price of $410.35, the stock is trading at approximately 96.0% of its 52-week range (52-week low of $160.59, 52-week high of $427.47), positioning it near the upper boundary of its annual range. This near-high positioning signals strong momentum but also raises the risk of overextension, particularly given the stock's beta of 1.534, which implies roughly 53% more volatility than the broader market. The maximum drawdown of -28.2% over the past year underscores that despite the strong trend, the stock is capable of sharp corrections, making position sizing and stop-loss discipline critical for risk management.
Short-term momentum is exceptionally strong and accelerating: the stock has gained 26.20% over the past month and 46.91% over the past three months, with relative strength versus SPY of +25.61% and +43.57% over those same periods. This represents a clear acceleration from the already impressive 97.30% six-month gain, suggesting the trend is not merely persistent but intensifying. The 1-month performance (+26.20%) significantly outpaces the 3-month (+46.91%) and 6-month (+97.30%) figures on a per-period basis, indicating that recent weeks have seen a step-change in buying pressure, likely catalyzed by the August 7, 2026 earnings release (which showed 37.7% revenue growth) and the September 23 Japan PMDA approval news. The short ratio of 4.12 suggests moderate short interest that could fuel further upside if the stock continues to grind higher, though it is not at levels that would signal an imminent short squeeze.
Key technical levels are well-defined: the 52-week high of $427.47 serves as immediate resistance, just 4.2% above the current price of $410.35, while the 52-week low of $160.59 represents the ultimate support level, though intermediate support likely exists around the $370-$390 zone where the stock consolidated in mid-September. A breakout above $427.47 would signal continuation of the primary uptrend and could open the door to new all-time highs, while a breakdown below the $370 area would suggest a deeper mean-reversion pullback toward the $320-$340 region. With a beta of 1.534 and a maximum drawdown of -28.2%, investors should recognize that this stock can move violently in both directions, and the current proximity to 52-week highs means the risk/reward for new entries is less favorable than it was at lower levels.
Beta
1.50
1.50x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$168-$437
Price range past year
Annual Return
+134.7%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +20.5% | +0.9% |
| 3m | +40.3% | +3.4% |
| 6m | +104.9% | +14.4% |
| 1y | +134.7% | +16.2% |
| ytd | +72.9% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is robust and accelerating, with Q2 2026 revenue of $752.75 million representing 37.71% year-over-year growth from $546.60 million in Q2 2025. Sequentially, revenue grew from $696.64 million in Q1 2026 to $752.75 million in Q2 2026, a 8.05% quarter-over-quarter increase, and the multi-quarter trend shows consistent acceleration: Q1 2025 revenue was $501.83 million, Q2 2025 was $546.60 million, Q3 2025 was $592.18 million, Q4 2025 was $665.50 million, Q1 2026 was $696.64 million, and Q2 2026 was $752.75 million. The product segment dominates revenue at $747.93 million, with oncology contributing $300,000 (likely a partial or misclassified figure), but the overall growth is clearly being driven by the Signatera oncology franchise and the core women's health business. This sustained top-line acceleration, combined with analyst revenue estimates of $5.99 billion for the current year, implies the company is successfully scaling its testing volumes and expanding reimbursement coverage.
Profitability remains a work in progress, but the trajectory is improving: Q2 2026 net income was -$66.97 million (net margin of -8.90%), a significant narrowing from -$100.94 million in Q2 2025 (net margin of -18.47%), and the company posted a rare positive net income of $47.26 million in Q4 2025 (net margin of 7.10%). Gross margin has been stable and high, ranging from 63.50% to 67.14% over the past six quarters, with Q2 2026 at 64.46%, reflecting the favorable economics of molecular diagnostics once tests are commercialized. Operating margin remains negative at -10.07% in Q2 2026, but this is a substantial improvement from -20.19% in Q2 2025, and the company's heavy investment in R&D ($228.07 million in Q2 2026, up from $146.43 million in Q2 2025) and SG&A ($327.20 million) reflects the costs of scaling a high-growth diagnostics platform. The narrowing losses and stable gross margins suggest that operating leverage is beginning to materialize as revenue scales.
The balance sheet is exceptionally strong, with a current ratio of 3.39, a debt-to-equity ratio of just 0.125, and $1.09 billion in cash at the end of Q2 2026, providing ample liquidity to fund operations without external financing. Free cash flow on a trailing twelve-month basis is positive at $71.70 million, though quarterly FCF has been volatile: -$8.64 million in Q2 2026, +$18.03 million in Q1 2026, +$37.82 million in Q4 2025, +$24.48 million in Q3 2025, and +$11.68 million in Q2 2025. Operating cash flow was $54.79 million in Q2 2026, and the company's ROE of -12.16% and ROA of -8.08% reflect the still-negative earnings, but the improving cash generation and fortress-like balance sheet suggest that Natera can self-fund its growth initiatives. The cash flow to debt ratio of 0.23 and interest coverage of -85.16 (negative due to operating losses) are less concerning given the minimal debt load and substantial cash reserves.
Quarterly Revenue
$752750000.0B
2026-06
Revenue YoY Growth
+37.7%
YoY Comparison
Gross Margin
64.5%
Latest Quarter
Free Cash Flow
$71697000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Because Natera's trailing net income is negative (EPS of -$0.0066, net margin of -9.03%), the PE ratio is not meaningful (trailing PE of -150.72), and the forward PE of -4314.93 is also distorted by near-term loss expectations. Therefore, the most appropriate primary valuation metric is the price-to-sales (PS) ratio, which stands at 13.58x trailing and 21.44x on an EV/Sales basis. The forward PS ratio, based on analyst revenue estimates of $5.99 billion, implies a forward PS of approximately 10.0x (using the current market cap of $59.75 billion), suggesting the market expects significant revenue growth to bring the multiple down. The gap between trailing and forward PS ratios reflects the market's confidence in continued top-line acceleration, though the absolute level of 13.58x is rich and prices in substantial future growth.
Compared to the broader Medical - Diagnostics & Research industry, where PS ratios typically range from 3x to 8x for profitable players and 5x to 15x for high-growth diagnostics companies, Natera's 13.58x PS ratio represents a premium of roughly 70-100% versus the sector median. This premium is justified by Natera's superior growth profile (37.7% YoY revenue growth versus industry average of 5-10%), its leadership in the high-growth MRD market, and its expanding gross margins (64.5% versus industry average of 50-55%). However, the premium also reflects the risk that if growth decelerates or reimbursement pressures emerge, the multiple could compress sharply. The PB ratio of 18.29x is also elevated, reflecting the asset-light nature of the diagnostics business and the market's willingness to pay up for intangible assets like the Signatera platform and clinical data moat.
Historically, Natera's PS ratio has ranged from a low of 17.27x in Q2 2022 to a high of 65.23x in Q3 2021, with the current 13.58x (based on trailing twelve-month revenue) sitting near the low end of its own historical band. This is notable because it suggests that despite the stock's massive price appreciation, the valuation multiple has actually compressed as revenue has grown faster than the share price. The current PS of 13.58x is well below the 5-year average of approximately 30x, indicating that the market is no longer pricing in the same level of speculative growth as it did in 2021. However, the forward PS of ~10x still embeds optimistic assumptions about continued 30%+ growth, and any slowdown could trigger multiple compression even if absolute revenue continues to rise.
PE
-150.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Natera's financial risks are primarily tied to its unproven path to sustained profitability and heavy reliance on continued revenue growth. Despite a 37.7% YoY revenue increase to $752.75 million in Q2 2026, the company reported a net loss of $66.97 million (net margin -8.90%) and negative operating cash flow of -$8.64 million for the quarter, though trailing twelve-month free cash flow is positive at $71.70 million. The balance sheet is strong with $1.09 billion in cash and a debt-to-equity ratio of 0.125, but the company's valuation depends on achieving the analyst-estimated EPS of $4.23, which would require a dramatic turnaround from the current trailing EPS of -$0.0066. Additionally, revenue concentration in the Signatera oncology franchise and women's health business means any slowdown in test volumes or reimbursement could disproportionately impact results.
Market and competitive risks are significant given the stock's premium valuation and high beta. The PS ratio of 13.58x and EV/Sales of 21.44x are well above the diagnostics sector median of 3x-8x, leaving the stock vulnerable to multiple compression if growth slows or if competitive pressures from Guardant Health and others intensify. The beta of 1.534 indicates the stock is 53% more volatile than the market, and with the price near the 52-week high of $427.47, any market-wide selloff could amplify losses. Regulatory and reimbursement risks are also prominent; while the recent Japan PMDA approval is a positive, any adverse reimbursement decisions in the U.S. or delays in international expansion could hinder growth. The high short ratio of 4.12 suggests some bearish sentiment, though not extreme.
In a worst-case scenario, a combination of decelerating revenue growth, reimbursement headwinds, and a market rotation away from high-multiple growth stocks could trigger a sharp correction. The 52-week low of $160.59 represents a potential downside of -60.9% from the current price of $410.35, while the analyst low target of $280.00 implies a -31.8% decline. A more realistic adverse scenario might see the stock retrace to the $280-$300 range, a loss of 27-32%, if growth slows to 20% and the PS multiple compresses to 8x. Given the maximum drawdown of -28.2% over the past year, investors should be prepared for significant volatility and potential losses in a bear case.
FAQ
The key risks for NTRA include: 1) Financial risk: persistent net losses (-$66.97 million in Q2 2026) and negative operating cash flow (-$8.64 million) despite revenue growth, with profitability not yet proven. 2) Valuation risk: trading at a premium PS of 13.58x vs. peers, with the stock above the average analyst target, leaving little room for error. 3) Competitive risk: intense competition in the MRD space from Guardant Health and others, which could erode market share and pricing. 4) Macro/regulatory risk: high beta of 1.534 makes the stock sensitive to market downturns, and reimbursement decisions could impact adoption. The most severe risk is a growth slowdown that triggers multiple compression, potentially causing a 30%+ decline.
The 12-month forecast for NTRA is balanced with a neutral stance. The base case (50% probability) sees the stock trading in the $360-$420 range, assuming 30-35% revenue growth and gradual margin improvement. The bull case (30% probability) targets $475-$520, driven by accelerated Signatera adoption and international expansion. The bear case (20% probability) targets $280-$320, if growth decelerates or reimbursement headwinds emerge. The most likely scenario is the base case, with the key assumption that revenue growth remains above 30% and the company continues to narrow losses. However, the stock's high volatility means outcomes can deviate significantly.
NTRA appears overvalued relative to its peers and analyst targets. The trailing PS ratio of 13.58x and EV/Sales of 21.44x are significantly above the diagnostics sector median of 3x-8x, representing a 70-100% premium. However, relative to its own history, the PS ratio is near the low end of its 5-year range (average ~30x), suggesting the multiple has compressed as revenue grew. The forward PS of ~10x still embeds optimistic growth assumptions. The market is pricing in continued 30%+ revenue growth and a successful path to profitability, which may be difficult to achieve. If growth slows, the stock could face multiple compression, making it overvalued at current levels.
At the current price of $410.35, NTRA is not an immediate buy due to its premium valuation and price exceeding the average analyst target of $361.16. The stock has surged 156.13% over the past year, and while revenue growth is impressive at 37.7% YoY, the company remains unprofitable with a net margin of -8.90%. The risk/reward is balanced: the high analyst target of $475.00 implies 15.75% upside, but the low target of $280.00 implies 31.76% downside. For long-term investors with high risk tolerance, a pullback to the $350-$370 range would offer a more attractive entry point. Short-term traders should be cautious given the high beta of 1.534 and proximity to the 52-week high.
NTRA is more suitable for long-term investment (minimum 3-5 years) given its growth stage, high volatility (beta 1.534), and lack of dividends. The company is still scaling its Signatera franchise and investing heavily in R&D ($228.07 million in Q2 2026), which should drive future growth but may cause near-term earnings volatility. Short-term trading is risky due to the stock's sharp moves (max drawdown -28.2% in the past year) and proximity to 52-week highs. Long-term investors can benefit from the multi-billion-dollar MRD opportunity if Natera executes on reimbursement and international expansion. A suggested minimum holding period is 3 years to allow for profitability and market penetration.